---

# SECURITIES AND EXCHANGE COMMISSION

# Washington, D.C. 20549

---

# FORM 10-QSB

---

# [X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR
15(d) OF THESECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2002

OR

# [  ] TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-24001

# IQ Biometrix, Inc.

Incorporated pursuant to the Laws of Delaware

Internal Revenue Service  Employer
Identification No. 76-0552098

10600 N. De Anza Boulevard, Suite 250, Cupertino, California 95014

(559) 222-2229

Former name if changed since last report

# JVWeb, Inc.

Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X]     No [  ]

The total number of shares of the registrants Common
Stock, $0.01 par value, outstanding on September 30, 2002: 16,484,285 shares.

Transitional Small Business Disclosure Format (check one):Yes 
[  ]     No [X]

---

`IQ BIOMETRIX, INC.
                         QUARTER ENDED DECEMBER 31, 2002

                                      INDEX

PART I.  FINANCIAL INFORMATION                                             Page

         Item 1.  Financial Statements

         Condensed financial statements of IQ Biometrix, Inc.:

            Consolidated balance sheet as of December 31, 2002                3

            Consolidated statement of operations for the
                  three months and six months ended December 31, 2002         4

            Consolidated statement of cash flows for the six
                  months ended December 31, 2002                              5

            Consolidated notes to financial statements                        6

         Item 2.  Management's Plan of Operations                             7

PART II. OTHER INFORMATION

         Item 4.     Controls and Procedures                                  9

         Item 6.     Exhibits and Reports on Form 8-K.                        9

                             (a)Exhibits

SIGNATURE                                                                    10

CERTIFICATIONS                                                               11`

# PART 1.   FINANCIAL INFORMATION

# Item 1.   Financial Statements

`IQ BIOMETRIX, INC.
                             (formerly JVWeb, Inc.)
                           CONSOLIDATED BALANCE SHEET
                               December 31, 2002


                  ASSETS
Current Assets
  Cash                                                              $    92,987
  Inventory of packaging supplies                                        19,000
                                                                    -----------
         Total Current Assets                                           111,986
                                                                    -----------
Intangible property, net of $35,919 accumulated depreciation             44,899
                                                                    -----------
TOTAL ASSETS                                                        $   156,885
                                                                    ===========



         LIABILITIES & STOCKHOLDERS' DEFICIT
Current Liabilities
    Convertible notes payable to investors                          $   350,000
    Demand note payable                                                  50,000
    Accounts payable and accrued expenses                               149,540
                                                                    -----------
         Total Current Liabilities                                      549,540
                                                                    -----------

STOCKHOLDERS' DEFICIT
  Common stock, $.01 par value, 50,000,000 shares
    authorized, 16,551,285 shares issued and outstanding                165,513
  Paid in capital                                                     1,253,128
  Deficit                                                            (1,811,296)
                                                                    -----------
         TOTAL STOCKHOLDERS' DEFICIT                                 (  392,655)
                                                                    -----------
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT                         $   156,885
                                                                    ===========`

`IQ BIOMETRIX, INC.
                             (formerly JVWeb, Inc.)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
      For the Three Months and Six Months Ended December 31, 2002 and 2001


                                             Three Months        Six Months
                                           Ended December 31, Ended December 31,
                                             2002     2001      2002      2001
                                           -------- ------   --------- ---------
Revenues                              $  28,305 $  37,248  $  49,387  $ 44,441

Operating Expenses
  Cost of sales                           6,502     4,218     14,122     5,218
  Selling                                37,056     5,267     85,884     5,267
  General and admin.                    328,869    30,817    611,162   106,219
  Write off of advance to
    former affiliate                     52,401               52,401
  Research and development               55,028               80,267
  Amortization                            6,735     6,735     13,470     8,980
  Interest                                9,112               19,112
                                      ---------  ---------  ---------  --------
  Total operating expenses              495,703    47,037    876,418   125,684
                                      ---------  ---------  ---------  --------
NET (LOSS)                            $(467,398) $( 9,789) $(827,031)$ (81,243)
                                      =========  =========  ========= =========

Basic and diluted
  loss per share                         $(.03)    $(.00)     $(.05)     $(.01)

Weighted average shares             16,517,785 14,580,000 16,502,785 14,580,000`

`IQ BIOMETRIX, INC.
                             (formerly JVWeb, Inc.)
                      STATEMENTS OF CONSOLIDATED CASH FLOWS
               For the Six Months Ended December 31, 2002 and 2001


                                                           2002        2001
CASH FLOWS FROM OPERATING ACTIVITIES                    ---------     ---------
  Net comprehensive loss                                $(827,031)  $( 81,243)
  Adjustments to reconcile net loss to net cash
    provided by operating activities:
    Amortization                                           13,470       8,980
    Stock warrants issued as interest on loans received    19,112
    Stock issued for services                              64,517      68,360
    Writeoff of advance to former affiliate                52,401
  Changes in:
    Accounts receivable                                               (  2,960)
    Additional cash advances to former affiliate         ( 26,121)
    Inventory of packaging supplies                        12,000        4,000
    Accounts payable and accrued expenses                  92,426        4,932
                                                        ---------     ---------
         NET CASH USED IN OPERATING ACTIVITIES           (599,226)       2,069
                                                        ---------     ---------

CASH FLOWS FROM FINANCING ACTIVITIES
  Proceeds from sale of common stock                      200,000
  Proceeds from new convertible notes payable             350,000
  Proceeds from demand note payable                        50,000
                                                         ---------
NET CASH PROVIDED BY FINANCING ACTIVITIES                 600,000
                                                         ---------    ---------
NET INCREASE (DECREASE) IN CASH                               774        2,069

CASH BALANCES
         - Beginning of period                             92,213
                                                         ---------    ---------
         - End of period                                $  92,987    $   2,069
                                                         =========    =========`

## IQ BIOMETRIX, INC.
                   CONSOLIDATED NOTES TO FINANCIAL STATEMENTS

## NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited
interim financial statements of IQ Biometrix, Inc. have been prepared in
accordance with accounting principles generally accepted in the United States of
America and the rules of the Securities and Exchange Commission
(SEC), and should be read in conjunction with the audited financial
statements and notes thereto contained in IQ Biometrixs 2002 Annual Report
filed with the SEC on Form 10-KSB (the Company was named JVWeb, Inc. at that
time). In the opinion of management, all adjustments, consisting of normal
recurring adjustments, necessary for a fair presentation of financial position
and the results of operations for the interim periods presented have been
reflected herein. The results of operations for interim are not necessarily
indicative of the results to be expected for the full year. Notes to the
financial statements which would substantially duplicate the disclosure
contained in the audited financial statements for 2002 as reported in the 10-KSB
have been omitted.

## NOTE 2 - CONVERTIBLE NOTES PAYABLE

During the last 6 months,
IQ Biometrix received $400,000 in total from 2 current stockholders and 2 new
stockholders. $350,000 was for 6% unsecured notes all due on August 1, 2003, and
convertible anytime by the holder into IQ Biometrix common stock at 80% of the
lower of the current market price or of any public offering price. To date there
have been no public offerings.

$50,000 was for a 10%
unsecured note payable on December 1, 2002 and which was not paid.

As an incentive to borrow
the money, IQ Biometrix issued 40,000 warrants at $.01. These warrants are
exercisable anytime for 5 years. These shares were recorded at their intrinsic
value of $19,112.

Accrued and unpaid interest
on these notes is $5,512 to date.

## NOTE 3 - STOCK ISSUANCES

During the 3 months ended
December 31, 2002, IQ Biometrix sold 500,000 shares for $200,000.

During the 6 months ended December 31, 2002, IQ Biometrix issued:

- 97,000 shares for services to advisors valued at $32,288.

- 210,000 options to outsiders recorded at their fair value using the
                  Black-Scholes method of $32,229.

-
1,220,000 options to insiders recorded at their intrinsic value of $0, where the
option exercise price equaled the market price on the grant dates.

## NOTE 4 - IMPAIRMENT

In the current quarter,
management determined that $52,401 advanced over the past 12 months to an entity
owned by a former shareholder Pierre Cote was uncollectible and written off.

## ITEM 2. MANAGEMENT'S PLAN OF OPERATION

## Summary

IQ Biometrix, Inc. is a
security software and services company headquartered in Cupertino, California
with offices in Houston, Texas and Fresno, California. We are a leading provider
of facial composite software to police and government agencies in North America,
with thousands of licenses of its FACESTM software, version 3.0, in
police departments, the US military, the Central Intelligence Agency and the
FBI.

The FACES technology is a
revolutionary tool that allows the creation and re-creation of billions of human
faces. This advanced technology can be used by any agency or organization whose
responsibility lies in the public safety and security arena. The unique
morphological coding of the FACES database (Intercode) of approximately 4,000
facial features has made it possible, for the first time, to set an industry
standard for the comparison of facial images from law enforcement agencies,
private security and businesses. Available now in beta form, FACES version 4.0
includes approximately 6,000 facial features.

As an update to our
previous plans for the year, as reported in our 10-K for FYE 6.30.02, we have
succeeded, in a modified form, in reaching our two main objectives:

o We have
launched a new version of our Faces product, which we have now called Faces LE
version 3.1, and related training and certification services,  and

o
We have developed an enterprise solution, which is currently being offered in a
beta stage, to certain markets, including the law enforcement and casino
industries.

Faces LE, v. 3.1:The launching of Faces LE, v. 3.1 includes a suite of related services. The
bundle of services will be offered as an integrated product/service offering.
The array of services being offered within this service package include:

o The
Faces 3.1 product. The products most significant upgrade from Faces 3.0,
is the integration with TRAK. TRAK, as we have previously disclosed, is a service offered by Social Tech, Inc. It allows any
police officer to create high-resolution photo bulletins and share them
electronically with other law enforcement jurisdictions, the media, and the
community where appropriate.

o
A product training course, which centers around using the Faces product in
interviewing witnesses to create a composite image of suspects

o A standardization and
authentication certification process for graduates of the training course, and

o
In the future, an on-line community where law enforcement professionals, as well
as interested civilians can congregate to share information, techniques, and success stories.

Enterprise Solutions:IQ Enterprise solutions capability has been launched to take fullest
advantage of both our intellectual property and our position in the marketplace.
The value created for the customers comes from a shift on what we sell and how
we execute. Our enterprise solutions practice will seek to acquire a greater
percentage of the business customers budget for security
technology-related projects.

Our efforts in this area
will be to focus on those customers that see themselves as having no choice but
to buy standard products to meet specific needs. The resulting systems either
never integrate properly or require great deal of professional service to be
integrated. The inexperience with technology and changing priorities set by
security concerns often diminishes the value of such information systems.

The objective of our
enterprise strategy is to tailor solutions rather than build products. The
solutions may include one or more product along with processes. The solutions
are not only geared to address current problems but takes into consideration
future needs. Such a combination of different technologies can then be packaged
as web services to eliminate technology obsolescence. This means the investment
towards a solution will only grow and not depreciate overtime. For early
adopters, the solution maybe offered with a SLA (service level agreement) to
guarantee returns.

As a result of the above,
we may reduce the additional financing requirements, previously estimated at
approximately $2.5 million, to complete the launching of its two new products
and reach break-even status. The sources of funding are anticipated to come
primarily from, a private placement of up to $1.0 million from an agreement that
was entered into with Forte Capital, and a material amount from revenue from
sales of its newly named Faces 3.1 product group which began in January of 2003.
There is no assurance that the company will be successful in attaining its
funding objectives, and will need to scale back operations to the extent full
funding is not attained.

A significant item to note
involves the existing inventory of Faces 3.0 product. In the acquisition of
IQBiometrix by JVWeb, Inc., the Faces 3.0 inventory was deemed obsolete by
management. As a result, no value for this inventory is represented on our
balance sheet. Subsequently, management has explored market applications for our
3.0 product that will add material longevity to its market potential. Although
this cannot be represented on our balance sheet, management estimates this
renewed role for Faces 3.0 has a revenue value of approximately $2 million.
There can be no assurance as to the ultimate realization or timing of that
revenue.

## General
Discussion

We
facea liquidity challenge. We require additional financing to continue
operations and remain a viable entity.

We
have a severe liquidity shortfall that impairs its ability to meet its current
operating cash flow requirements in the near term. As of fiscal quarter end,
December 31, 2002, our cash balance totaled less than $93,000. At quarter end,
our accounts payable were $144,028 with $107,479 owed to related parties
consisting of accrued payroll and reimbursable expenses. We estimate a required
monthly cash inflow of $110,000 from a combination of revenue and financing
activities to meet our present level of obligations. We make no assurance that
this level of financing can be achieved. We are maintaining a consistent effort
to locate sources of additional funding. Should we fail to meet our obligations,
both past and as they come due, through additional financing or increased
revenue, we will not be able to remain a viable entity.

On
February 11, 2002, we signed an agreement with Forte Capital whereby Forte will
purchase an unspecified number of shares of our stock for $1,200,000 in the
aggregate with the initial funding occurring before November 22, 2002 with
additional funding occurring in 2003. Part of the agreement calls for the
exercise of warrants of our common shares by Forte Capital. We have no assurance
that the warrants will be exercised. Should Forte Capital not exercise its
warrants, we will have the immediate need to seek alternative financing. As of
quarters end, we have received $200,000 for 500,000 of our common shares,
or $.40 per share. We are also negotiating another financing opportunity related
to a convertible debenture offer.

## Financial
Information

Our
gross revenue in the 6 months ending December 31, 2002 of $49,387 was
exclusively generated by license revenue of Faces 3.0 software. Sales of $44,441
were made in the initial period from July 10, 2001 (date of inception) through
December 31, 2001. Since IQ Biometrix only began selling product in the fall of
2001, there is no relevance to prior fiscal quarters comparisons.

We
expect our Faces 4.0 product to be market ready in the 4th quarter of fiscal
2003. We began an aggressive sales and marketing campaign to institutionalize
the use of our software in law enforcement. Concurrently, we are pursuing
contracts among, but not exclusively with, the casino industry, local, state,
and national citizen alerts associations, and original equipment manufacturers
in the computer industry.

Revenue
from our latest quarter was from a diverse retail customer base sold mainly in
units of 1 to 50. No customer made up more than 2% of gross revenue. Gross
profit margin for the period was 71%.

Sales
and marketing expense for the past 6 months was $85,884, or 174% of gross
revenue. The majority of the expense is related to personnel and public
relations.

General
and administrative expenses for the past 6 months was $611,162 or 1,237% of
gross revenue. Most of our general and administrative expense is due to
personnel and professional services. We maintain our primary office in
Cupertino, California, with satellite offices in Fremont, California and
Houston, Texas. At December 31, 2002, we employed 10 full-time people, and had
various independent contractors to advise on market condition, product
feasibility, fund raising, and employee relations. Our total personnel expense
including advisors was $390,950 or 64% of total general and administrative
expense, and 44% of total expenses. Travel and entertainment costs total $35,468
we set forth our best effort to gain a foothold in an extremely competitive
marketplace.

Research
and development expenses for the past 6 months were $80,267 or 162% of gross
revenue. The total is due to contracted and internal work associated with the
development costs of producing Faces 4.0, our next marketable product. A beta
version has already been established with a market feasibility delivery date of
the final version occurring in early 2003. We anticipate fiscal year 2003
expenses of $75,000 to complete the Faces 4.0 software platform. We are actively
pursuing other engineering and development opportunities to create a suite of
products and services to compliment and enhance the Faces 4.0 software. We
expect engineering and development costs to be 11 to 13 percent in fiscal 2003
of total costs.

Accrued
interest expense for the quarter was $5,512. We began issuing a 6% convertible
subordinated debenture up to $1,000,000 beginning in first quarter of fiscal
2003. $50,000 of the debenture has been subscribed in the quarter for a current
fiscal year total of $450,000 in total borrowings. This debenture shall bear
interest at the rate of six percent (6%) per annum from the issue date through
the maturity date. All notes will be payable August 1, 2003. We shall pay such
interest in cash on the maturity date; however, if we elect to redeem any of the
debentures prior to the maturity date, we may pay the interest due upon
redemption. We also agreed to pay bonus interest on each issue date
of 10,000 of our common shares for every $100,000 principal amount of the
debentures.

We
owe no income taxes since inception.

We incurred
a net loss of $467,398, or $0.03 per share loss for the quarter ending December
31, 2002.

# PART II. OTHER INFORMATION

# Item 2.           Changes in Securities

On
November 15, 2002, the Company entered in an preliminary agreement with Forte
Capital that provided for Forte to purchase 500,000 shares of the Companys
common stock at an aggregate purchase price of $200,000.  This preliminary
agreement also provided that the Company would issue to Forte warrants to
purchase an additional 1,000,000 shares of the Companys common stock at a
base exercise price of $1.00 per warrant, adjustable downward to some extent if
the average closing price of the Companys common stock during a month were
less than $1.00.  During the quarter ended December 31, 2002, Forte honored
the preliminary agreement and purchased the 500,000 shares at an aggregate
purchase price of $200,000.  The Company and Forte finalized their
agreements during February 2003, during which time the warrants described above
were issued.  The issuances of the 500,000 shares and the warrants to
purchase the additional 1,000,000 shares are claimed to be exempt, and the
issuances of the common stock underlying the warrants will be claimed to be
exempt, pursuant to Regulation D under the Securities Act of 1933.

# Item 4.           Controls and Procedures

Within 90 days prior to the filing of this Quarterly  Report on Form 10-Q,  the chief  executive  officer and chief  financial
officer of the Company  evaluated the  effectiveness  of the Company's  disclosure  controls and procedures and have concluded that the
Company's  controls and  procedures  are  effective in timely  alerting  them to material  information  required to be disclosed in the
reports that are filed or submitted under the Securities and Exchange Act of 1934.  There have been no significant  changes in internal
controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation.

# Item 6.  Exhibits and Reports on Form 8-K

(a)      The following exhibits are filed with this Quarterly Report or
are incorporated herein by reference:

`Exhibit
                  Number                    Description

                  10.01                     Asset Purchase Agreement
                  10.02                     Stock Purchase Agreement
                  10.03                     Warrant Agreement
                  10.06                     Bill of Sale and Assignment
                  99.03                     Certifications Required Pursuant to
                                                Section 906 of the Sarbanes-
                                                Oxley Act of 2002.

(b)      Reports on Form 8-K

                           NONE`

# SIGNATURES

Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.

IQ BIOMETRIX, INC.

|By | /s/William Scigliano
                  William Scigliano
Chief Executive Officer | 
|-- | -------------------------------------------------------------------------------- | 

Dated:  February 19, 2003

`CERTIFICATION

         I, William Scigliano, Chief Executive Officer of IQ Biometrix, Inc.,
         certify that:

         1.       I have reviewed this quarterly report on Form 10-QSB of IQ
                  Biometrix, Inc.;

         2.       Based on my knowledge, this  quarterly report does not contain
                  any untrue  statement of a material fact or omit to state a
                  material fact necessary to make the  statements made, in light
                  of the  circumstances under which such  statements  were made,
                  not  misleading  with  respect to the period  covered by this
                  quarterly report;

         3.       Based on my knowledge, the financial statements,  and other
                  financial information included in this quarterly report,
                  fairly  present in all material  respects the financial
                  condition,  results of operations and cash flows of the
                  registrant as of, and for, the periods presented in this
                  quarterly report;

         4.       The  registrant's  other  certifying  officers  and I  are
                  responsible  for  establishing  and  maintaining disclosure
                  controls and  procedures (as defined in Exchange Act Rules
                  13a-14 and 15d-14) for the registrant and have:

                  (a)      designed such disclosure  controls and procedures to
                           ensure that material  information  relating to the
                           registrant, including its consolidated  subsidiaries,
                           is made known to us by others within those entities,
                           particularly during the period in which this
                           quarterly report is being prepared;

                  (b)      evaluated the  effectiveness  of the registrant's
                           disclosure  controls and procedures as of a date
                           within 90 days prior to the filing date of this
                           quarterly report (the "Evaluation Date"); and

                  (c)      presented in this  quarterly  report our  conclusions
                           about the  effectiveness  of the  disclosure controls
                           and procedures based on our evaluation as of the
                           Evaluation Date;

         5.       The registrant's other certifying  officers and I have
                  disclosed,  based on our most recent  evaluation,  to the
                  registrant's  auditors and the audit committee of registrant's
                  board of directors (or persons performing the equivalent
                  functions):

                  (a)      all significant deficiencies in the design or
                           operation of internal controls which could adversely
                           affect the registrant's  ability to record,  process,
                           summarize and report financial data and have
                           identified for the registrant's auditors any material
                           weaknesses in internal controls; and

                  (b)      any fraud, whether  or not  material,  that  involves
                           management  or other employees who have a significant
                           role in the registrant's internal controls; and

         6.       The  registrant's  other  certifying  officers and I have
                  indicated in this quarterly  report whether or not there were
                  significant  changes in internal  controls or in other factors
                  that could  significantly  affect internal controls subsequent
                  to the date of our most recent  evaluation,  including any
                  corrective  actions with regard to significant deficiencies
                  and material weaknesses.

February 19, 2003

/s/ William Scigliano
         William Scigliano
         Chief Executive Officer`

`CERTIFICATION

        I, Greg J. Micek, President and Chief Financial Officer of IQ Biometrix,
 Inc., certify that:

         1.       I have reviewed this quarterly report on Form 10-QSB of IQ
                  Biometrix, Inc.;

         2.       Based on my knowledge, this  quarterly report does not contain
                  any untrue  statement of a material fact or omit to state a
                  material fact necessary to make the  statements made, in light
                  of the  circumstances under which such  statements  were made,
                  not  misleading  with  respect to the period  covered by this
                  quarterly report;

         3.       Based on my knowledge, the financial statements,  and other
                  financial information included in this quarterly report,
                  fairly  present in all material  respects the financial
                  condition,  results of operations and cash flows of the
                  registrant as of, and for, the periods presented in this
                  quarterly report;

         4.       The  registrant's  other  certifying  officers  and I  are
                  responsible  for  establishing  and  maintaining disclosure
                  controls and  procedures (as defined in Exchange Act Rules
                  13a-14 and 15d-14) for the registrant and have:

                  (a)      designed such disclosure  controls and procedures to
                           ensure that material  information  relating to the
                           registrant, including its consolidated  subsidiaries,
                           is made known to us by others within those entities,
                           particularly during the period in which this
                           quarterly report is being prepared;

                  (b)      evaluated the  effectiveness  of the registrant's
                           disclosure  controls and procedures as of a date
                           within 90 days prior to the filing date of this
                           quarterly report (the "Evaluation Date"); and

                  (c)      presented in this  quarterly  report our  conclusions
                           about the  effectiveness  of the  disclosure controls
                           and procedures based on our evaluation as of the
                           Evaluation Date;

         5.       The registrant's other certifying  officers and I have
                  disclosed,  based on our most recent  evaluation,  to the
                  registrant's  auditors and the audit committee of registrant's
                  board of directors (or persons performing the equivalent
                  functions):

                  (a)      all significant deficiencies in the design or
                           operation of internal controls which could adversely
                           affect the registrant's  ability to record,  process,
                           summarize and report financial data and have
                           identified for the registrant's auditors any material
                           weaknesses in internal controls; and

                  (b)      any fraud, whether  or not  material,  that  involves
                           management  or other employees who have a significant
                           role in the registrant's internal controls; and

         6.       The  registrant's  other  certifying  officers and I have
                  indicated in this quarterly  report whether or not there were
                  significant  changes in internal  controls or in other factors
                  that could  significantly  affect internal controls subsequent
                  to the date of our most recent  evaluation,  including any
                  corrective  actions with regard to significant deficiencies
                  and material weaknesses.
February 19, 2003

/s/ Greg J. Micek
         Greg J. Micek
         President and Chief Financial Officer`

`CERTIFICATIONS

         I, William Scigliano, certify that:

         1.       I have reviewed this Quarterly Report on Form 10-QSB of IQ
                  Biometrix, Inc.;

         2.       Based on my knowledge,  this  Quarterly  Report does not
                  contain any untrue  statement of a material fact or omit to
                  state a  material  fact  necessary  to make  the  statements
                  made,  in light of the circumstances  under which such
                  statements  were made,  not  misleading  with respect to the
                  period covered by this Quarterly Report; and

         3.       Based on my knowledge,  the financial  statements,  and other
                  financial information included in this Quarterly  Report,
                  fairly  present in all material  respects the  financial
                  condition,  results of operations  and  cash  flows of the
                  registrant as of,  and  for,  the  periods  presented  in this
                  Quarterly Report.

         /s/ William Scigliano
         William Scigliano                  Date: February 19, 2003
         Chief Executive Officer


         I, Greg J. Micek, certify that:

         1.       I have reviewed this Quarterly Report on Form 10-QSB of IQ
                  Biometrix, Inc.;

         2.       Based on my knowledge,  this  Quarterly  Report does not
                  contain any untrue  statement of a material fact or omit to
                  state a  material  fact  necessary  to make  the  statements
                  made,  in light of the circumstances  under which such
                  statements  were made,  not  misleading  with respect to the
                  period covered by this Quarterly Report; and

         3.       Based on my knowledge,  the financial  statements,  and other
                  financial information included in this Quarterly  Report,
                  fairly  present in all material  respects the  financial
                  condition,  results of operations  and  cash  flows of the
                  registrant as of,  and  for,  the  periods  presented  in this
                  Quarterly Report.


         /s/ Greg J. Micek
         Greg J. Micek                     Date: February 19, 2003
         President and Chief Financial Officer`